Antibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center

Size: px
Start display at page:

Download "Antibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center"

Transcription

1 Antibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center

2 Case 1 60 yo healthy female admitted for fevers and dysuria. No history of previous pyelonephritis. On admission, temperature 102. BP stable. Pulse 105 but after a liter of fluid comes down to 84. WBC 20 with left shift; creatinine 1.0; UA with 140 wbc. Urine sent for culture. Blood cultures drawn. Patient started on ceftriaxone. Patient does not look ill. Complaining of dysuria.

3 Case 1 continued Laboratory calls you the next day and tells you both urine and blood are growing gram negative rods Patient feels better. No more fevers. CBC 14 Blood pressure and pulse ok

4 Next step? a. Continue ceftriaxone b. Start Zosyn since gram negative may be pseudomonas c. Start cefepime since it has better pseudomonal coverage than Zosyn d. Start ciprofloxacin in preparation for discharge with oral ciprofloxacin

5 Next step? a. Continue ceftriaxone b. Start Zosyn since gram negative may be pseudomonas c. Start cefepime since it has better pseudomonal coverage than Zosyn d. Start ciprofloxacin in preparation for discharge with oral ciprofloxacin

6 Case 2 60 yo male transferred from SNF for fever Long time resident of SNF due to multiple medical conditions Has foley catheter Febrile with leukocytosis. BP 85/40; P130; R26 Patient looks ill Chest xray clear. UA with pyuria and looks cloudy Creatinine 0.8

7 Case 2 continued Patient s blood pressure drops and patient intubated Levophed and ADH required to maintain BP Nurse about to start phenylephrine SNF calls and states that blood from yesterday is growing gram negative rods which are lactose negative and look like pseudomonas. Urine also with gram negative rods.

8 Next step? a. Start Zosyn b. Start cefepime c. Start meropenem d. Start cefepime and amikacin

9 Next step? a. Start Zosyn b. Start cefepime c. Start meropenem d. Start cefepime and amikacin

10 Lactose fermenters Characteristic of gram negative organisms Ability of organism to use lactose as food source Fermenters: E. coli, Enterobacter, Klebsiella Non-fermenters: Pseudomonas, Acinetobacter, Stenotrophomonas

11 Gram negative agents Penicillins Cephalosporins Carbapenems Fluoroquinolones Aminoglycosides Polymixins Aztreonam New agents

12 Penicillins Penicillin, oxacillin, nafcillin, dicloxacillin really no gram negative coverage Amoxicillin/clavulanate (Augmentin) and ampicillin/sulbactam (Unasyn) has some gram negative coverage including anaerobes (not reliable for E. coli so do not use for abdominal infections). Can use for aspiration pneumonia Piperacillin/tazobactam (Zosyn) broadest coverage including pseudomonas and anaerobes Zosyn sometimes active against ESBL and can use in urine infections due to ESBL

13 Cephalosporins Gram negative coverage increases as you go from 1 st to 3 rd generation and gram positive coverage decreases Only ceftazidime and cefepime will cover pseudomonas Ceftazidime has no gram positive coverage Limited anaerobic coverage except cefoxitin and cefotetan Cefepime sometimes active against ESBL and can use in urine infections due to ESBL No enterococcal coverage

14 Carbapenems Ertapenem, imipenem, and meropenem Most reliable agents against ESBL Meropenem and imipenem will cover pseudomonas Ertapenem will not reliably cover pseudomonas and enterococcus and penicillin resistant S. pneumoniae Meropenem considered better than imipenem for gram negatives Imipenem considered better than meropenem for gram positives Some concern with imipenem and seizure threshold

15 Fluoroquinolones Levofloxacin, ciprofloxacin, moxifloxacin Broad gram negative coverage including pseudomonas (not moxifloxacin) Pretty good gram positive coverage (levofloxacin, moxifloxacin better than ciprofloxacin) Moxifloxacin has better anaerobic coverage and can use for abdominal infection Need to add Flagyl to levofloxacin and ciprofloxacin for colonic infections to cover anaerobes Watch out for QT prolongation and tendinitis and tendon rupture

16 Aminoglycosides Amikacin, gentamicin, tobramycin Excellent gram negative coverage including pseudomonas No gram positive coverage Very little tissue penetration Good for bacteremia, endovascular infections, and urine infections Nephrotoxic and ototoxic Need to measure levels

17 Polymixins Polymixin E (Colistin), polymixin B Stopped using decades ago. Started using again 10 years ago due to MDR gram negative infections Excellent gram negative coverage including pseudomonas, acinetobacter, ESBL, carbapenem resistant enterobacteriaceae (CRE) No gram positive coverage Limited tissue penetration Good for bacteremia, endovascular infections Doesn t concentrate in urine like aminoglycosides but still nephrotoxic

18 Aztreonam Purely gram negative agent including coverage for pseudomonas Not active against ESBL or CRE Can use in penicillin allergic patients Can not use it for patients allergic to ceftazidime

19 New gram negative agents Ceftolozane/Tazobactam (ZERBAXA) Recently FDA approved Has in vitro activity against gram negative pathogens including Pseudomonas and most ESBL enterobacteriaceae Limited CRE coverage Limited activity against gram positive pathogens Equally effective as Levaquin for complicated urinary tract infections Equally effective as Meropenem for complicated intra-abdominal infections (included ESBL) when combined with Flagyl Limited activity against Acinetobacter Ceftazidime/Avibactam (AVYCAZ) Recently FDA approved Has in vitro activity against gram negative pathogens including Pseudomonas and most ESBL enterobacteriaceae Some CRE activity (KPC) Limited activity against gram positive pathogens Equally effective as Imipenem for complicated urinary tract infections Equally effective as Meropenem for complicated intra-abdominal infections when combined with Flaygl Limited activity against Acinetobacter

20 Empiric treatment of gram negative bacteremia Before you have sensitivities Really depends on how sick the patient is and how much you need to be right initially One end of the spectrum is patient from community and stable (case 1) The other end of the spectrum is patient in hospital or from SNF and in septic shock (case 2) Unfortunately a lot of patients fall in between these 2 spectrums and in the end it s clinical judgement

21 Case 1 From the community Probably going to be regular E. coli (non-esbl) Low likelihood of resistant gram negative organism Willing to take small chance of being wrong because patient is stable

22 Case 2 From SNF (they have the highest rates of resistant organisms) Need to cover pseudomonas completely 2 antibiotics might increase the chance of appropriate empirical therapy Can t be wrong as patient critically ill Need to save life before kidneys

23 UCI Antibiogram 2016

24 Empiric treatment of gram negative bacteremia Most patients fall in between 2 ends of spectrum Even with scenario 2, the answer is controversial No evidence that 2 gram negative agents better than 1 in septic shock Both monotherapy and combination therapy are endorsed by Surviving Sepsis Campaign (grade 1b) In the end, it s clinical judgement Call ID fellow or me Why not put everyone with gram negative bacteremia on meropenem?

25 Carbapenem resistant enterobacteriaceae (CRE) at UCI 2011: 2 cases 2016: 50 cases

26 Case 3 70 yo male with Parkinson s disease admitted for frequent falls Fell today and hit head. CT with small subdural hematoma and patient admitted Denies fevers, chills, sob, cough, dysuria. Complaining of fatigue more than usual. He thinks he needs his Parkinson medications adjusted On admission, afebrile, blood pressure stable. Looks tired but not ill WBC 14 with 85% neutrophils but no left shift UA negative Blood cultures drawn

27 Case 3 continued Next day lab informs you that ¼ blood culture bottles with Staphylococcus aureus, sensitivities pending Patient doing well. Wants to go home. Afebrile. WBC 15.

28 Next step? a. Start vancomycin b. Start daptomycin c. Start linezolid d. Start Bactrim e. No antibiotics since it is probably contaminant given only ¼ bottles and patient with no signs of infection

29 Next step? a. Start vancomycin b. Start daptomycin c. Start linezolid d. Start Bactrim e. No antibiotics since it is probably contaminant given only ¼ bottles and patient with no signs of infection

30 Case 3 continued Next day the other 3 bottles are positive and organism identified as MRSA with vancomycin MIC<0.5; sensitive to daptomycin, linezolid, synercid, gentamicin, rifampin, Bactrim TTE shows 0.5 cm vegetation of native mitral valve Vancomycin continued with good trough levels 5 days later, patient doing well but blood still growing MRSA. Vancomycin MIC still <0.5

31 Next step? In addition to looking for another source of infection: a. Keep vancomycin b. Start daptomycin c. Add gentamicin to vancomycin d. Add rifampin to vancomycin e. Start linezolid

32 Next step? In addition to looking for another source of infection: a. Keep vancomycin b. Start daptomycin c. Add gentamicin to vancomycin d. Add rifampin to vancomycin e. Start linezolid

33 Staphylococcus aureus Staphylococcus aureus should not be treated as a contaminant Vancomycin is still the mainstay of therapy Combination therapy only for prosthetic valve endocarditis (gentamicin, rifampin) and hardware associated osteomyelitis with retention of hardware (rifampin) Think about failure after 7 days of persistent cultures IDSA guidelines high dose daptomycin with another agent recommended if true failure (B-III)

34 Antimicrobial failure is rare Usually due to lack of source control Abscess Natural course of disease rather than antimicrobial failure Aspiration pneumonia Endovascular infections Other staphylococcus aureus infections

35 Vancomycin Still the mainstay therapy Indicated for all infections Be careful with acute kidney injury Some concern over efficacy recently but this is debatable (MIC creep) Only 14 cases of vancomycin resistant staphylococcus aureus in US total

36 Daptomycin FDA approved for right sided endocarditis and skin/soft tissue infection Can t use for pneumonia Can increase CPK Can become resistant during treatment Reports of eosinophilic pneumonia

37 Clindamycin FDA approved for serious S. aureus (not MRSA) infections Used in children with MRSA infections causing septic arthritis, osteomyelitis, pneumonia, and lymphadenitis Excellent tissue penetration except brain Inducible resistance can be present so lab needs to D zone test Used mainly for skin/soft tissue infections in adults But based on pediatric data, probably can use in pneumonia, osteomyelitis, septic arthritis Excellent bioavailability

38 Linezolid FDA approved for skin/soft tissue infection and pneumonia Can cause serotonin syndrome in patients taking SSRI s Myelosuppression (reversible), neuropathy side effects (not reversible) Less resistance reported than daptomycin No clear evidence that linezolid better than vancomycin for nosocomial pneumonia Not recommended for bacteremia (bacteriostatic) and failures reported

39 Tetracyclines Doxycycline FDA approved for skin/soft tissue infection due to S. aureus Data lacking for more invasive infections Minocycline may still work if resistant to doxycycline Tygacil also improved for intra-abdominal infections. Don t use for bacteremia.

40 Bactrim Not FDA approved for any S. aureus infection Still used quite a bit for skin/soft tissue infection Not a lot o f data for invasive infection Recent open label randomized trial failed to show non-inferiority of Bactrim versus vancomycin (OR 1.4)

41 Synercid FDA approved for skin/soft tissue infections Rarely used these days Usually now for VRE resistant to daptomycin and linezolid High incidence of arthralgias

42 Ceftaroline 5 th generation cephalosporin FDA approved for community acquired pneumonia and skin/soft tissue infection Has gram negative coverage in addition to MRSA coverage $400 per day

43 MRSA: Treatment of serious infections For endocarditis, bacteremia, pneumonia, osteomyelitis, necrotizing fasciitis, vancomycin is still first line Daptomycin for bacteremia, endocarditis, osteomyelitis, necrotizing fasciitis Linezolid for pneumonia Clindamycin for pneumonia (based on data on pediatrics) and skin/soft tissue infections, osteomyelitis, septic arthritis Bactrim and doxycycline for skin/soft tissue infections

44 Case 4 45 yo female is admitted with C. difficile colitis C. difficile PCR positive with NAP1 strain Multiple episodes of diarrhea per day Patient febrile with WBC 22K Creatinine 1.8 (previously normal) Tachycardic which responds to 1 liter NS Abdomen mildly distended and tender CT scan with colitis in descending colon but no ileus

45 Next step? a. Start po Flagyl b. Start po vancomycin c. Start fidaxomicin d. Start po vancomycin and IV Flagyl

46 Next step? a. Start po Flagyl b. Start po vancomycin c. Start fidaxomicin d. Start po vancomycin and IV Flagyl

47 Case 4 continued Patient starts to get hypotensive requiring levophed 10 mcg Transferred to unit WBC increases to 38K Still having profuse diarrhea No ileus on imaging

48 Next step? a. Add po Flagyl b. Add IV Flagyl c. Add fidaxomicin d. Add IV Flagyl and rectal vancomycin

49 Next step? a. Add po Flagyl b. Add IV Flagyl c. Add fidaxomicin d. Add IV Flagyl and rectal vancomycin

50 Treatment of C. difficile colitis Mild (leukocytosis<15k; creatinine<1.5 times baseline): use po Flagyl Severe (leukocytosis>15; creatinine>1.5 times baseline): use po vancomycin Severe, complicated (critically ill, hypotension, megacolon, ileus): use po vancomycin, IV Flagyl, rectal vancomycin (if you suspect ileus) Do not add IV Flagyl unless it is severe and complicated No evidence that increased doses of vancomycin better but most physicians would do it Can get high serum levels of po vancomycin with prolonged therapy in patients with renal failure New guidelines coming soon

51 C. Difficile testing at UCI Can only be ordered on non-formed stool Can not have other causes of diarrhea (laxatives, tube feeds) Both PCR and toxin EIA reported PCR too sensitive Some data that toxin EIA correlates better with C. difficile colitis JAMA study that showed for PCR+/toxinpatients, treatment had no effect on outcome

52 C. Difficile testing at UCI PCR-/toxin- PCR+/toxin+ PCR-/toxin+ PCR+/toxin- Do not treat for C. difficile colitis Treat for C. difficile colitis Treat for C. difficile colitis Do not treat unless signs of toxicity present (patient sick) Formal UCI guidelines coming soon

53 Case 5 You get called by lab on MICU patient with positive cultures for yeast. Patient hospitalized with severe MI and heart failure. Underwent CABG and prolonged hospital course complicated by nosocomial pneumonia requiring Zosyn. Blood cultures drawn 2 days ago for fevers. Blood positive only from IJ. Peripheral negative. Still febrile but stable.

54 Next step? a. Start fluconazole b. Start fluconazole and pull IJ c. Start micafungin and pull IJ d. Pull IJ only since yeast likely colonizer

55 Next step? a. Start fluconazole b. Start fluconazole and pull IJ c. Start micafungin and pull IJ d. Pull IJ only since yeast likely colonizer

56 Candidemia Candidemia is never treated as contaminant Potential for bad complications, endophthalmitis and endocarditis If suspect line, needs to come out Get ophthalmologic consult for exam Get echocardiogram if endocarditis suspected Empiric therapy with micafungin in case non-albicans candida (glabrata only 50% sensitive to fluconazole) Candida glabrata identified 39/57 cases at UCI last year

57 Case 6 72 yo diabetic male admitted for infected foot ulcer Ulcer present for months but has been draining for last month and more last couple of days Exam shows 3 cm deep ulcer (but not to bone) with some erythema. Some drainage but not purulent Afebrile WBC 14 Patient looks good ER has sent superficial swab of ulcer to microbiology MRI with acute osteomyelitis

58 Next step? a. Start vancomycin and Zosyn and follow up swab cultures. b. No antibiotics for now. Start antibiotics after microbiology results back. c. Hold antibiotics. Consult orthopedics. d. Start vancomycin and Zosyn. Consult orthopedics.

59 Next step? a. Start vancomycin and Zosyn and follow up swab cultures. b. No antibiotics for now. Start antibiotics after microbiology results back. c. Hold antibiotics. Consult orthopedics. d. Start vancomycin and Zosyn. Consult orthopedics.

60 Case 6 continued Orthopedic services states no surgical intervention required

61 Next step? a. Start vancomycin and Zosyn and treat for 6 weeks b. Await swab cultures results and then direct therapy based on results c. Get ID consult d. Ask orthopedic service for bone biopsy for culture or deep specimen for culture before starting antibiotics

62 Next step? a. Start vancomycin and Zosyn and treat for 6 weeks b. Await swab cultures results and then direct therapy based on results c. Get ID consult d. Ask orthopedic service for bone biopsy for culture or deep specimen for culture before starting antibiotics

63 IDSA Practice Guideline on Diabetic Foot Infections When and how should I obtain specimen(s) for culture from a patient with a diabetic foot wound? Recommendations For clinically uninfected wounds, we recommend not collecting a specimen for culture (strong, low). For infected wounds, we recommend that clinicians send appropriately obtained specimens for culture prior to starting empiric antibiotic therapy, if possible. Cultures may be unnecessary for a mild infection in a patient who has not recently received antibiotic therapy (strong, low). We recommend sending a specimen for culture that is from deep tissue, obtained by biopsy or curettage and after the wound has been cleansed and debrided. We suggest avoiding swab specimens, especially of inadequately debrided wounds, as they provide less accurate results (strong, moderate).

64 Bone Biopsy ID physicians want it Surgeons say it is not necessary. Reasoning is that bone cultures are unreliable and you are going to treat with broad spectrum antibiotics anyway since diabetic foot osteomyelitis is usually polymicrobial ID physicians will point out cultures positive in 87% cases and still benefit in narrowing antibiotics Swabs unreliable. Concordance with bone cultures only 50% What do the guidelines say?

65 Bone Biopsy Uptodate: Bone biopsy (open or percutaneous) should be obtained for pathogen identification and to obtain susceptibility data when this is feasible IDSA Practice Guideline Diabetic Foot Osteomyelitis: Obtaining a bone specimen for culture (and histology, when available), is most likely to be justified when there is: Uncertainty regarding the diagnosis of osteomyelitis despite clinical and imaging evaluations An absence (or confusing mix) of culture data from soft tissue specimens Failure of the patient to respond to empiric antibiotic therapy A desire to use antibiotic agents that may be especially effective for osteomyelitis but have a high potential for selecting resistant organisms (eg, rifampin, fluoroquinolones)

66 Bone Biopsy: How do you put it together? IDSA Practice Guideline does not give FIRM recommmendation to obtain bone biopsy in all cases of diabetic foot osteomyelitis If you can avoid vancomycin or broad spectrum abx, you should Retrospective study showed better outcomes with bone culture guided therapy versus none (56% vs 22%) Nevertheless reports of 76% success rates with empiric therapy alone

67 When do you have to start antibiotics right away? And when should you wait until you can get proper cultures? Make every attempt to get cultures if you know that treatment will be prolonged Hardware associated osteomyelitis Diabetic foot infections Endovascular infections Decision to start antibiotics right away depends on the infection and how the sick the patient is Septic shock: Start right away Meningitis: Start right away Bad pneumonia: Start right away Endocarditis: Depends If symptoms have been going on for a while, safe to wait If unsure, call ID fellow or Antimicrobial Stewardship Program attending (me)

68 THE END

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at Malignant Otitis Externa Inflammation and damage at the base of the skull due to an untreated outer ear P. aeruginosa most common organism Yellow-green drainage from the ear Odor Fever Deep inner ear pain

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

Antibiotic stewardship in long term care

Antibiotic stewardship in long term care Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016 Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection

More information

SHC Clinical Pathway: HAP/VAP Flowchart

SHC Clinical Pathway: HAP/VAP Flowchart SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal

More information

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic

More information

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare 100% of all wounds will yield growth If you get a negative culture you something is wrong! Pseudomonas while ubiquitous does

More information

General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship

General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship General Surgery Small Group Activity (Facilitator Notes) Curriculum for Antimicrobial Stewardship Facilitator instructions: Read through the facilitator notes and make note of discussion points for each

More information

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review (1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

Antimicrobial Stewardship: The Premier Health Experience

Antimicrobial Stewardship: The Premier Health Experience Antimicrobial Stewardship: The Premier Health Experience Steve Burdette, MD, FIDSA Professor of Medicine Wright State University Boonshoft School of Medicine Director of Antimicrobial Stewardship Miami

More information

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity

More information

Antimicrobial Stewardship Program

Antimicrobial Stewardship Program Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels

More information

Provincial Drugs & Therapeutics Committee Memorandum Version 2

Provincial Drugs & Therapeutics Committee Memorandum Version 2 Provincial Drugs & Therapeutics Committee Memorandum Version 2 16 Garfield Street 16, rue Garfield PO Box 2000, Charlottetown C.P. 2000, Charlottetown Prince Edward Island Île-du-Prince-Édouard Canada

More information

Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults

Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults Health PEI: Provincial Antibiotic Advisory Team Empiric Antibiotic Treatment Guidelines for Sepsis Syndromes in Adults COMMUNITY-ACQUIRED PNEUMONIA HEALTHCARE-ASSOCIATED PNEUMONIA INTRA-ABDOMINAL INFECTION

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Discussion Points. Decisions in Selecting Antibiotics

Discussion Points. Decisions in Selecting Antibiotics Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

3/20/2011. Code 215 of Hammurabi: If a physician performed a major operation on

3/20/2011. Code 215 of Hammurabi: If a physician performed a major operation on The Good Antibiotics: the Good, the Bad and the Ugly John P. Cello, MD Professor of Medicine and Surgery, University of California, San Francisco Most organisms can be readily identified by culture, special

More information

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014 H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Antibiotics 201: Gramnegatives

Antibiotics 201: Gramnegatives Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

This survey was sent only to EIN members with a pediatric infectious diseases practice.

This survey was sent only to EIN members with a pediatric infectious diseases practice. Infectious Diseases Society of America Emerging Infections Network Report for Query: Pediatric Outpatient Parenteral Antibiotic Therapy (OPAT) Overall response rate: 188/281 (66.9%) physicians responded

More information

Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and

Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Health-Care Associated Infections Overall Goals & Objectives:

More information

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,

More information

Antimicrobial Therapy

Antimicrobial Therapy Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the

More information

CLINICAL USE OF BETA-LACTAMS

CLINICAL USE OF BETA-LACTAMS CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial

More information

THERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS

THERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS THERAPY OF ANAEROBIC INFECTIONS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu LUNG ABSCESS A lung abscess is a localized pus cavity in

More information

Diagnosis: Presenting signs and Symptoms include:

Diagnosis: Presenting signs and Symptoms include: PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery

RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis

More information

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report to 214 Table of Contents I. Introduction..

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Dr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College

Dr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and

More information

Effectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of

Effectiv. q3) Purpose of Policy. Pharmacy: Antimicrobial subcommp&tittee of Name ofpolicynupolicy:mber: Department: Approving Officer: Responsible Agent: Scope: Protected Antimicrobials 3364-133-106 Pharmacy: Antimicrobial subcommp&tittee of Chief Executive Officer Director of

More information

Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO

Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Update on Fluoroquinolones Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO Potential fluoroquinolone side-effects Increased risk, greater than with most other antibiotics, for

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

Objectives. Review basic categories of intra-abdominal infection and their respective treatments. Community acquired intra-abdominal infection

Objectives. Review basic categories of intra-abdominal infection and their respective treatments. Community acquired intra-abdominal infection Objectives Review basic categories of intra-abdominal infection and their respective treatments Community acquired intra-abdominal infection Mild/Moderate Severe Acute biliary tract infections Nosocomial

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Antimicrobial Chemotherapy

Antimicrobial Chemotherapy 2016 edition by Claudine El-Beyrouty, PharmD, BCPS Department of Pharmacy Thomas Jefferson University Hospital Brian Roslund, PharmD, BCPS, AQ-ID Department of Pharmacy Thomas Jefferson University Hospital

More information

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic

More information

HOW TO INTERPRET CULTURE RESULTS. Karen Brust, MD November 29, 2012

HOW TO INTERPRET CULTURE RESULTS. Karen Brust, MD November 29, 2012 HOW TO INTERPRET CULTURE RESULTS Karen Brust, MD November 29, 2012 DISCLOSURES NONE CULTURE RESULTS Based on susceptibility patterns CLSI: international, interdisciplinary, Nonprofit,

More information

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance 22nd Congress of the EAHP "Hospital pharmacists catalysts for change", 22-24 March 2017, Cannes Disclosure

More information

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier

More information

Rational use of antibiotics

Rational use of antibiotics Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis

More information

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals

Diabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)

More information

Clinical Practice Standard

Clinical Practice Standard Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:

More information

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management

More information

The Rise of Antibiotic Resistance: Is It Too Late?

The Rise of Antibiotic Resistance: Is It Too Late? The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the

More information

Antibiotic Updates: Part I

Antibiotic Updates: Part I Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Infectious Disease Issues in the Intensive Care Unit

Infectious Disease Issues in the Intensive Care Unit Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic

More information

Septicaemia Definitions 1

Septicaemia Definitions 1 Septicaemia Definitions 1 Term Definition Bacteraemia Systemic Inflammatory response (SIRS) Sepsis Bacteria that can be cultured from the blood stream The systemic response to a wide range of stresses.

More information

Resistant Infections: Superbugs and No Superdrugs

Resistant Infections: Superbugs and No Superdrugs Resistant Infections: To the SNF and Back Elizabeth Hudson, DO, MPH Department of Infectious Diseases Panorama City 9/15/12 Superbugs and No Superdrugs Antibiotics are often taken for granted Changes over

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Stanford Antimicrobial Safety and Sustainability Program Antimicrobial Restriction Policy

Stanford Antimicrobial Safety and Sustainability Program Antimicrobial Restriction Policy I. Purpose Stanford Antimicrobial Safety and Sustainability Program Antimicrobial Restriction Policy The goal of the Stanford Antimicrobial Safety and Sustainability Program (SASS) at Stanford Healthcare

More information